A hnRNPA2B1 agonist effectively inhibits HBV and SARS-CoV-2 omicron in vivo.

A hnRNPA2B1 agonist effectively inhibits HBV and SARS-CoV-2 omicron in vivo.
复制标题

hnRNPA2B1 激动剂在体内有效抑制 HBV 和 SARS-CoV-2 omicron

DOI:
10.1093/procel/pwac027
复制
发表时间:
2023-01
期刊:
影响因子:
21.1
通讯作者:
Xu, Min
Xu, Min
中科院分区:
生物学1区
文献类型:
--
作者:
Zuo, Daming;Chen, Yu;Cai, Jian-piao;Yuan, Hao-Yang;Wu, Jun-Qi;Yin, Yue;Xie, Jing-Wen;Lin, Jing-Min;Luo, Jia;Feng, Yang;Ge, Long-Jiao;Zhou, Jia;Quinn, Ronald J.;Zhao, San-Jun;Tong, Xing;Jin, Dong-Yan;Yuan, Shuofeng;Dai, Shao-Xing;Xu, Min

文献摘要

参考文献

相似文献

21世纪已经发生了十多次重大流行病或病毒性疾病大流行,包括毁灭性的COVID-19。迫切需要具有广谱覆盖的新型有效抗病毒药物。在此,我们报道了一种新的广谱抗病毒化合物PAC5。在不同的HBV感染小鼠模型中,口服PAC5可消除HBV cccDNA并降低大抗原负荷。引人注目的是,在SARS-CoV-2组粒(BA.1)感染的仓鼠模型中口服PAC5可显著降低病毒载量并减轻肺部炎症。在机制上,PAC5与hnRNPA2B1的RNA识别基序中Asp49附近的一个口袋结合。pac5结合的hnRNPA2B1被广泛激活并转运到细胞质中,在那里它启动TBK1-IRF3途径,导致产生具有抗病毒活性的I型ifn。我们的研究结果表明,PAC5是hnRNPA2B1的一种新型小分子激动剂,可能在现在和未来处理新发传染病中发挥作用。
The twenty-first century has already recorded more than ten major epidemics or pandemics of viral disease, including the devastating COVID-19. Novel effective antivirals with broad-spectrum coverage are urgently needed. Herein, we reported a novel broad-spectrum antiviral compound PAC5. Oral administration of PAC5 eliminated HBV cccDNA and reduced the large antigen load in distinct mouse models of HBV infection. Strikingly, oral administration of PAC5 in a hamster model of SARS-CoV-2 omicron (BA.1) infection significantly decreases viral loads and attenuates lung inflammation. Mechanistically, PAC5 binds to a pocket near Asp49 in the RNA recognition motif of hnRNPA2B1. PAC5-bound hnRNPA2B1 is extensively activated and translocated to the cytoplasm where it initiates the TBK1-IRF3 pathway, leading to the production of type I IFNs with antiviral activity. Our results indicate that PAC5 is a novel small-molecule agonist of hnRNPA2B1, which may have a role in dealing with emerging infectious diseases now and in the future.
TLR8激动剂GS-9688(Selgantolimod)在慢性肝炎B中的治疗潜力:抗病毒和调节介质的重塑。
DOI: 10.1002/hep.31695
发表时间: 2021-07
期刊: Hepatology (Baltimore, Md.)
影响因子: --
作者:
Amin OE;Colbeck EJ;Daffis S;Khan S;Ramakrishnan D;Pattabiraman D;Chu R;Micolochick Steuer H;Lehar S;Peiser L;Palazzo A;Frey C;Davies J;Javanbakht H;Rosenberg WMC;Fletcher SP;Maini MK;Pallett LJ
通讯作者: Pallett LJ
DOI: 10.1093/nar/gkv007
发表时间: 2015-04-20
影响因子: 14.9
作者:
Ritchie ME;Phipson B;Wu D;Hu Y;Law CW;Shi W;Smyth GK
通讯作者: Smyth GK
DOI: 10.1126/science.8009221
发表时间: 1994-06-24
期刊: SCIENCE
影响因子: 56.9
作者:
MULLER, U;STEINHOFF, U;AGUET, M
通讯作者: AGUET, M
DOI: 10.1016/j.chom.2020.12.016
发表时间: 2021-02-10
影响因子: 30.3
作者:
Guo Q;Zhao Y;Li J;Liu J;Yang X;Guo X;Kuang M;Xia H;Zhang Z;Cao L;Luo Y;Bao L;Wang X;Wei X;Deng W;Wang N;Chen L;Chen J;Zhu H;Gao R;Qin C;Wang X;You F
通讯作者: You F
DOI: 10.1186/1471-2105-10-168
发表时间: 2009-06-02
期刊: BMC bioinformatics
影响因子: 3
作者:
Le Guilloux V;Schmidtke P;Tuffery P
通讯作者: Tuffery P